Gazette.govt.nzPursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicines which were referred to the Minister of Health under the provisions of section 24(5) of the Act and are set out in the Schedule hereto:
Schedule
| Product: | Opdivo (40mg/4mL) |
| Active Ingredient: | Nivolumab 10mg/mL |
| Dosage Form: | Concentrate for infusion |
| New Zealand Sponsor: | Bristol-Myers Squibb (NZ) Limited |
| Manufacturers: | Vetter Pharma-Fertigung GmbH & Co KG, Ravensburg, Germany Bristol-Myers Squibb Holdings Pharma Limited, Manati, Puerto Rico |
| Product: | Opdivo (100mg/10mL) |
| Active Ingredient: | Nivolumab 10mg/mL |
| Dosage Form: | Concentrate for infusion |
| New Zealand Sponsor: | Bristol-Myers Squibb (NZ) Limited |
| Manufacturers: | Vetter Pharma-Fertigung GmbH & Co KG, Ravensburg, Germany Bristol-Myers Squibb Holdings Pharma Limited, Manati, Puerto Rico |
| Product: | Zinnat |
| Active Ingredient: | Cefuroxime axetil 300.72mg equivalent to cefuroxime 250mg |
| Dosage Form: | Film coated tablet |
| New Zealand Sponsor: | GlaxoSmithKline NZ Limited |
| Manufacturer: | Glaxo Operations UK Limited t/a Glaxo Wellcome Operations, Barnard Castle, United Kingdom |
Dated this 7th day of March 2022.
CHRIS JAMES, Group Manager, Medsafe, Ministry of Health (pursuant to delegation given by the Minister of Health on 11 September 2013).